Australian Clinical Labs Ltd (ASX: ACL) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Australian Clinical Labs Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$486.42 million
P/E Ratio
31.59
Dividend Yield
4.13%
Shares Outstanding
201.83 million
Earnings per share
0.077
Dividend per share
0.10
Year To Date Return
-15.22%
Earnings Yield
3.17%
Franking
100%
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Australian Clinical Labs Ltd (ASX: ACL)
Latest News
Broker Notes
Brokers name 3 ASX shares to buy today
Share Gainers
Why Australian Clinical Labs, Magellan, Sandfire, and Telix shares are rising
Healthcare Shares
Why the Australian Clinical Labs (ASX:ACL) share price is up 10% to a record high
Share Gainers
Why Australian Clinical Labs, Humm, Neometals, and Viva Energy are rising
Small Cap Shares
Analysts are tipping huge gains for these small cap ASX shares
Healthcare Shares
2 ASX healthcare shares rated as buys
Broker Notes
Experts love these 2 ASX shares punching above their weight
Broker Notes
Brokers name 2 ASX healthcare shares to buy
Healthcare Shares
Australian Clinical Labs (ASX:ACL) share price on watch following profit upgrade
Share Gainers
Australian Clinical Labs (ASX:ACL) share price soars 9% after smashing profit forecast
Share Market News
2 ASX shares liked by this top fund manager
Share Market News
These 2 ASX shares have been named as opportunities
Frequently Asked Questions
-
Yes, Australian Clinical Labs has historically paid two fully franked shareholder dividends a year.
-
Australian Clinical Labs generally pays its shareholder dividends in April and September.
-
Australian Clinical Labs Ltd listed on the ASX on 14 May 2021.
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 28 Mar 2024 | $0.0300 | 100.00% | Interim | 26 Apr 2024 |
| 27 Mar 2023 | $0.0700 | 100.00% | Interim | 26 Apr 2023 |
| 23 Aug 2022 | $0.4100 | 100.00% | Final | 15 Sep 2022 |
| 25 Mar 2022 | $0.1200 | 100.00% | Interim | 21 Apr 2022 |
ACL ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Australian Clinical Labs Ltd
Australian Clinical Labs Ltd (ASX: ACL) is a leading provider of pathology services in Australia. The company's 75 laboratories perform more than 12 million episodes annually with a network of more than 1,300 collection centres in every Australian state and territory except Tasmania. The company is also among the largest private hospital pathology businesses in the country, providing services to more than 90 private and public hospitals.
Its services include all routine pathology tests, advanced pathology, pregnancy screening, non-invasive prenatal testing, chemical pathology, haematology, histopathology, immunology, serology and microbiology, and commercial drug and alcohol testing.
In ACL's established regions of Western Australia, Victoria, New South Wales, Queensland, South Australia, and the Northern Territory, the company has an equivalent market position in community pathology to its rivals Sonic Healthcare Ltd (ASX: SHL) and Healius Ltd (ASX: HLS). The company says it also has a growing presence in the Australian Capital Territory.
ACL Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 02 May 2024 | $2.41 | $-0.01 | -0.41% | 337,958 | $2.41 | $2.46 | $2.40 |
| 01 May 2024 | $2.42 | $-0.01 | -0.41% | 296,828 | $2.42 | $2.45 | $2.41 |
| 30 Apr 2024 | $2.43 | $-0.02 | -0.82% | 94,036 | $2.49 | $2.49 | $2.43 |
| 29 Apr 2024 | $2.45 | $-0.01 | -0.41% | 144,588 | $2.50 | $2.55 | $2.45 |
| 26 Apr 2024 | $2.46 | $-0.03 | -1.20% | 246,118 | $2.50 | $2.50 | $2.45 |
| 24 Apr 2024 | $2.49 | $0.05 | 2.05% | 198,250 | $2.47 | $2.51 | $2.46 |
| 23 Apr 2024 | $2.44 | $0.03 | 1.24% | 258,572 | $2.40 | $2.46 | $2.40 |
| 22 Apr 2024 | $2.41 | $0.04 | 1.69% | 246,086 | $2.37 | $2.43 | $2.36 |
| 19 Apr 2024 | $2.37 | $-0.03 | -1.25% | 389,364 | $2.40 | $2.42 | $2.36 |
| 18 Apr 2024 | $2.40 | $-0.01 | -0.41% | 394,021 | $2.41 | $2.43 | $2.40 |
| 17 Apr 2024 | $2.41 | $-0.02 | -0.82% | 243,802 | $2.41 | $2.43 | $2.40 |
| 16 Apr 2024 | $2.43 | $-0.02 | -0.82% | 426,991 | $2.44 | $2.44 | $2.38 |
| 15 Apr 2024 | $2.45 | $-0.07 | -2.78% | 401,853 | $2.52 | $2.52 | $2.44 |
| 12 Apr 2024 | $2.52 | $-0.02 | -0.79% | 122,739 | $2.54 | $2.55 | $2.52 |
| 11 Apr 2024 | $2.54 | $-0.01 | -0.39% | 136,813 | $2.60 | $2.60 | $2.51 |
| 10 Apr 2024 | $2.55 | $0.01 | 0.39% | 115,172 | $2.54 | $2.58 | $2.53 |
| 09 Apr 2024 | $2.54 | $-0.06 | -2.31% | 411,983 | $2.56 | $2.60 | $2.52 |
| 08 Apr 2024 | $2.60 | $-0.01 | -0.38% | 240,129 | $2.63 | $2.65 | $2.56 |
| 05 Apr 2024 | $2.61 | $-0.03 | -1.14% | 1,223,375 | $2.60 | $2.67 | $2.60 |
| 04 Apr 2024 | $2.64 | $-0.03 | -1.12% | 113,035 | $2.67 | $2.69 | $2.61 |
| 03 Apr 2024 | $2.67 | $-0.02 | -0.74% | 1,405,378 | $2.67 | $2.71 | $2.65 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 28 Feb 2024 | Christine Bartlett | Buy | 20,000 | $47,154 |
On-market trade. As per announcement on 05-03-2024
|
| 20 Dec 2023 | Melinda McGrath | Issued | 395,490 | $901,717 |
Issue of securities. vwap, 880,836 Rights, As per announcement on 04-01-2024
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Michael Thomas Alscher | Non-Executive DirectorNon-Executive Chairman | Dec 2020 |
Mr Alscher is the Managing Partner and founder of Crescent, an Australian private equity investment firm, specialising in growth companies and certain industry sectors such as healthcare. He is Chair of Risk Committee. Prior to founding Crescent in 2000, Michael was a strategy consultant at Bain International and LEK Partnership as well as holding several senior operating roles. He is also member of the Risk Committee.
|
| Dr Leanne Rowe | Non-Executive Director | Apr 2021 |
Dr Rowe is a clinical professor and medical practitioner with over 30 years of clinical experience in the public and private health systems across acute care, aged care, mental health, and community health. Leanne is currently a Non-Executive Director of Bupa ANZ Group and a Presiding Member for Medical Panels Victoria.
|
| Mr Andrew Mark Rendle Dutton | Non-Executive Director | Apr 2021 |
Mr Dutton has over 30 years of management, business development and technology experience across Australia, Asia and Europe. Andrew is the current Chair of Land Registry Services and was recently an Advisor to FinancialForce APJ. He has had Chief Executive Officer and Board experience globally and within Australia. He is also member of the Risk Committee.
|
| Mr Nathanial Jonothan Thomson | Non-Executive Director | Dec 2020 |
Mr Thomson is a Partner at Crescent, an Australian private equity investment firm. Nathanial has over 20 years of experience in strategy consulting, private equity, and investment banking. He has consulting experience from his prior role at McKinsey & Co.
|
| Ms Christine Nildra Bartlett | Non-Executive Director | Aug 2023 |
Ms Bartlett has executive experience gained through chief executive officer and senior executive roles with National Australia Bank Limited, IBM and Jones Lang LaSalle. Christine has held roles with national and global responsibilities and has a strong commercial perspective, particularly in fostering innovation and leveraging new emerging technologies.
|
| Mr Mark Haberlin | Non-Executive Director | Apr 2021 |
Mr Haberlin has over 25 years of audit, risk management, capital transactions and mergers and acquisitions experience across industries including healthcare, real estate, and financial services. Mark is the Lead Independent Director and Chair of the Audit and Risk Committee of Abacus Property Group. Previously, Mark was an independent Non-Executive Director and the Chair of the Audit and Risk Committee of Laybuy Group Holdings Limited, the Chair of PwC Australia and PwC's Public Reporting Panel, as well as a Director of the European Australia Business Council and PwC Asia Pacific. He is also member of the Risk Committee.
|
| Ms Melinda Leigh McGrath | Chief Executive OfficerExecutive Director | Dec 2020 |
Ms McGrath has been the Chief Executive Officer and Executive Director of ACL's predecessor corporate vehicle, Clinical Laboratories Pty Ltd since 2015. Melinda has led the organization's restructure and transformation, building ACL's scale and operational performance improvement over the past seven years, overseeing the integration of Healthscope's Australian pathology business, St John of God Health Care's pathology business, Perth Pathology, SunDoctors and MedLab Pathology. She has also driven the establishment of one performance-oriented culture across the organization, via one unified integrated pathology system.
|
| Ms Eleanor Padman | Company Secretary |
-
|
|
| James Davison | Chief Financial Officer |
-
|
|
| Eleanor Padman | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Crescent Capital Partners V Lp. | 34,579,411 | 17.13% |
| Hsbc Custody Nominees (Australia) Limited | 33,314,369 | 16.51% |
| J P Morgan Nominees Australia Pty Limited | 25,262,126 | 12.52% |
| Citicorp Nominees Pty Limited | 20,122,838 | 9.97% |
| National Nominees Limited | 13,940,616 | 6.91% |
| Instanz Nominees Pty Ltd | 9,514,668 | 4.71% |
| Ccp Trusco 1 Pty Ltd | 8,919,642 | 4.42% |
| BNP Paribas Noms Pty Ltd | 5,961,920 | 2.95% |
| Ccp Trusco 2 Pty Ltd | 3,908,488 | 1.93% |
| Melinda Mcgrath | 2,173,867 | 1.08% |
| Hsbc Custody Nominees (Australia) Limited i | 2,131,656 | 1.06% |
| Perpetual Corporate Trust Ltd | 2,084,287 | 1.02% |
| Perpetual Corporate Trust Ltd i | 1,786,533 | 0.89% |
| ACL Employee Share Trusco Pty Ltd | 1,330,743 | 0.66% |
| Mr Nicholas Barry Debenham & Mrs Annette Cecilia Debenham | 1,080,800 | 0.54% |
| Dr Anthony James Landgren | 838,211 | 0.42% |
| Anthony Friedli | 754,390 | 0.37% |
| A.C.N. 633 176 100 Pty Ltd | 749,464 | 0.37% |
| Akat Investments Pty Limited | 600,000 | 0.30% |
| Paul Gerard Richard | 574,649 | 0.28% |
